

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 31/275</b>		<b>A1</b>	(11) International Publication Number: <b>WO 95/19770</b> (43) International Publication Date: 27 July 1995 (27.07.95)
(21) International Application Number: PCT/US95/00871 (22) International Filing Date: 20 January 1995 (20.01.95) (30) Priority Data: 08/184,383 21 January 1994 (21.01.94) US (71) Applicant: SEPRACOR, INC. [US/US]; 33 Locke Drive, Marlborough, MA 01752 (US). (72) Inventor: GRAY, Nancy, M.; 261 DeSimone Drive, Marlbor- ough, MA 01752 (US). (74) Agents: HANSEN, Philip, E. et al.; Heslin & Rothenberg, P.C., 5 Columbia Circle, Albany, NY 12203 (US).		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>	
(54) Title: METHODS AND COMPOSITIONS FOR TREATING ANDROGEN-DEPENDENT DISEASES USING OPTICALLY PURE R-(-)-CASODEX			
(57) Abstract  Methods and compositions are disclosed utilizing optically pure R-(-)-casodex for the treatment of androgen-dependent prostate cancer, while substantially reducing the concomitant liability of adverse effects associated with the central antiandrogen activity of the racemic mixture of casodex. R-(-)-casodex is a peripherally selective antiandrogen and is therefore useful in the treatment of other conditions supported by androgen or caused by elevated androgen levels. Such conditions include benign prostatic hypertrophy or hyperplasia, acne and hirsutism.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

-1-

METHODS AND COMPOSITIONS FOR TREATING ANDROGEN-  
DEPENDENT DISEASES USING  
OPTICALLY PURE R-(-)-CASODEX


BACKGROUND OF THE INVENTION

5        This invention relates to novel compositions of  
matter containing optically pure R-(-)-casodex. These  
compositions possess potent activity in treating  
prostate cancer, benign prostatic hypertrophy or  
hyperplasia, acne and hirsutism and other diseases  
10    including those that would benefit from a selective  
peripheral androgen antagonist. Optically pure R-  
(-)-casodex provides this treatment while  
substantially reducing adverse effects including, but  
not limited to, gynecomastia, breast tenderness, hot  
15    flushes, and other sequelae of central antiandrogen  
activity, which are associated with the  
administration of the racemic mixture of casodex.  
Also disclosed are methods for treating the above  
described conditions in a human while substantially  
20    reducing the adverse effects that are associated with  
the racemic mixture of casodex by administering the  
R-(-) isomer of casodex to said human.

      The active compound of these compositions and  
methods is an optical isomer of casodex. The  
25    preparation of racemic casodex is described in U.S.  
Patent 4,636,505. Chemically, the active compound  
is the (-) isomer of N-[4-cyano-3-(trifluoromethyl)  
phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-  
methylpropanamide, also known as 4'-cyano-3-[(4-  
30    fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-3'-  
(trifluoromethyl)propionanilide, hereinafter referred  
to as casodex. The absolute stereochemistry of the

-2-

(-) isomer is believed to be R as shown in formula I:



I

R-(-)-casodex, which is the subject of the  
5 present invention, is not presently commercially  
available. All of the clinical studies that have  
been reported have utilized the racemic mixture.

Many organic compounds exist in optically active  
forms, i.e., they have the ability to rotate the  
10 plane of plane-polarized light. In describing an  
optically active compound, the prefixes D and L or R  
and S are used to denote the absolute configuration  
of the molecule about its chiral center(s). The  
prefixes d and l or (+) and (-) are employed to  
15 designate the sign of rotation of plane-polarized  
light by the compound, with (-) or l meaning that the  
compound is levorotatory. A compound prefixed with  
(+) or d is dextrorotatory. There is no correlation  
between nomenclature for the absolute stereochemistry  
20 and for the rotation of an enantiomer. Thus, D-  
lactic acid is the same as (-) lactic acid, and L-  
lactic acid is (+). For a given chemical structure,  
these chiral compounds exist as a pair of enantiomers  
which are identical except that they are non-  
25 superimposable mirror images of one another. A  
specific stereoisomer may also be referred to as an  
enantiomer, and a mixture of such isomers is often  
called an enantiomeric or racemic mixture.

-3-

Stereochemical purity is of importance in the field of pharmaceuticals, where 12 of the 20 most prescribed drugs exhibit chirality. A case in point is provided by the L-form of the beta-adrenergic blocking agent, propranolol, which is known to be 100 times more potent than the D-enantiomer.

Furthermore, optical purity is important since certain isomers may actually be deleterious rather than simply inert. For example, it has been suggested that the D-enantiomer of thalidomide was a safe and effective sedative when prescribed for the control of morning sickness during pregnancy, while the corresponding L-enantiomer has been believed to be a potent teratogen.

The chromatographic separation of a diastereomeric pair of R-camphanoyl esters of racemic casodex and their hydrolysis and oxidation to (+)-casodex and (-)-casodex on a milligram scale is described by Tucker and Chesterson, J. Med. Chem. 31, 885-887 (1988). The ED<sub>50</sub> of R-(-)-casodex in inhibiting androgen in rats was reported to be 0.5 mg/kg in vivo.

Racemic casodex has been in clinical trials for use in prostate cancer. [See Kennealey and Furr, Urol. Clin. North Am. 18, 99-110 (1991); Mahler and Denis, J. Steroid Biochem. Molec. Biol. 37, 921-924 (1990); and Newling, Eur. Urol. 18 (Suppl), 18-21 (1990)]. The results of the preliminary clinical studies indicated that racemic casodex might be clinically useful in treating prostate cancer and other androgen-dependent diseases because of its

-4-

antagonist activity at peripheral androgen receptors, but that it gave rise to altered serum testosterone and a high incidence of side effects associated therewith.

5           Androgens have been implicated in the progression of several diseases, including human prostate cancer, where they appear to provide the major hormonal support for cancer cells. It is generally accepted that antiandrogens can play an  
10   important role in the endocrine treatment strategy for patients with prostate cancer. Racemic casodex has been found to be a very selective antagonist at peripheral androgen receptors in preclinical studies in animals. In these preclinical studies little if  
15   any agonist component and no progestational or glucocorticoid activity was observed.

          In human volunteers doses of 10-50 mg p.o. per day resulted in a 50 to 60% reduction in prostatic acid phosphatase levels. Over half the patients  
20   receiving racemic casodex at 30 or 50 mg reported gynecomastia and breast tenderness, about 20% reported hot flushes, and less than 10% reported nausea and vomiting, bone pain, confusion, constipation, headache, diarrhea, dyspepsia, fatigue,  
25   dizziness or rash. Significant elevations of serum testosterone, estradiol and LH (central effects) were observed at all doses, indicating that in humans, racemic casodex is less peripherally selective.

          The average half life for racemic casodex,  
30   estimated from oral studies, was about 8 days. Clinical trials have so far been limited to prostate

-5-

cancer. If the centrally mediated side effects could be eliminated, a relatively pure peripheral antiandrogen, as racemic casodex was originally thought to be, would be useful to treat benign  
5 prostatic hypertrophy or hyperplasia, acne and hirsutism and other androgen-dependent diseases.

Thus it would be particularly desirable to find a compound with the advantages shown by the racemic mixture of casodex in preclinical trials but without  
10 the aforementioned disadvantages.

#### SUMMARY OF THE INVENTION

It has now been discovered that the optically pure (-) isomer of casodex is an effective agent for treating androgen-dependent prostate cancer, benign  
15 prostatic hypertrophy or hyperplasia, acne, hirsutism and other diseases including those that would benefit from a selective antiandrogen. The optically pure (-) isomer of casodex provides this effective treatment while substantially reducing the adverse  
20 effects of racemic casodex that arise from central antiandrogen activity. These include, but are not limited to, gynecomastia, breast tenderness, hot flushes, and elevations of serum testosterone, estradiol and LH. Other side effects that may be  
25 ameliorated include nausea and vomiting, bone pain, confusion, constipation, headache, diarrhea, dyspepsia, fatigue, dizziness, and rash. The present invention also includes methods for treating the above described conditions in a human while  
30 substantially reducing the adverse effects that are

-6-

associated with the racemic mixture of casodex by administering the optically pure (-) isomer.

#### DETAILED DESCRIPTION OF THE INVENTION

5 The present invention encompasses a method of treating prostate cancer, which comprises administering to a human in need of such therapy, an amount of R-(-)-casodex, substantially free of its (+) stereoisomer, said amount being sufficient to retard the growth of the cancer. The method  
10 substantially reduces the concomitant liability of adverse effects associated with the administration of the racemic compound.

The present invention also encompasses a composition for the treatment of a human afflicted  
15 with prostate cancer, which comprises a therapeutically effective amount of R-(-)-casodex, substantially free of its (+) stereoisomer, and a pharmaceutically acceptable carrier.

A further aspect of the present invention  
20 includes a method of treating a condition supported by androgen or caused by elevated androgen levels in a human, which comprises administering to a human in need of such therapy, an amount of R-(-)-casodex, substantially free of its (+) stereoisomer,  
25 sufficient to block a majority of peripheral androgen receptors. The method substantially reduces the concomitant liability of adverse effects associated with the administration of racemic casodex. Conditions that may be treated with an antiandrogen  
30 in humans may include, but are not limited to, benign



-7-

prostatic hypertrophy or hyperplasia, acne and hirsutism.

In addition, the invention encompasses a composition for the treatment of a condition supported by androgen or contributed to by elevated androgen levels in a human which comprises a therapeutically effective amount of R-(-)-casodex, substantially free of its (+) stereoisomer, and a pharmaceutically acceptable carrier.

10

The racemic mixture of casodex (i.e., a 1:1 mixture of the two enantiomers) exhibits anticancer activity through its selective and potent antiandrogen activity, but this antiandrogen activity is, in humans, unfortunately not restricted to peripheral receptors. The lack of peripheral selectivity of the racemate thus gives rise to a high level of unacceptable side effects. Utilizing the optically pure or substantially optically pure isomer of R-(-)-casodex results in enhanced efficacy, diminished adverse effects and, accordingly, an improved therapeutic index by eliminating the central antiandrogen activity of the S enantiomer, thus providing therapy and a reduction of symptoms in a variety of conditions and disorders related to the activation of peripheral receptors in the presence of androgen in disadvantageous amounts. It is therefore more desirable to use the (-) isomer of casodex than to administer the racemic mixture.

25  
30

The term "adverse effects" includes, but is not limited to, gynecomastia, breast tenderness, hot flushes, nausea and vomiting, bone pain, confusion,

-8-

constipation, headache, diarrhea, dyspepsia, fatigue, dizziness, rash and alterations of serum testosterone, estradiol and LH.

The term "substantially free of its (+) stereoisomer" as used herein means that the compositions contain at least 90% by weight of R-(-)-casodex and 10% by weight or less of (+) casodex. In a more preferred embodiment the composition contains at least 99% by weight of R-(-)-casodex, and 1% or less of (+) casodex. In the most preferred embodiment, the composition contains greater than 99% by weight of R-(-)-casodex. These percentages are based upon the total amount of casodex in the composition. The terms "substantially optically pure (-) isomer of casodex" or "substantially optically pure R-(-)-casodex" and "optically pure (-) isomer of casodex" and "optically pure R-(-)-casodex" are also encompassed by the above-described amounts.

The term "treating prostate cancer" as used herein means treating, alleviating or palliating such condition, suppressing the growth of cancerous tissue and thus providing increased survival time.

The term "treating a condition supported by androgen or contributed to by elevated levels of androgen" as used herein means treating, alleviating or palliating such disorders, thus providing relief from the symptoms of the aforementioned conditions or slowing the progression of the disease. Among such conditions are benign prostatic hypertrophy or hyperplasia, acne and hirsutism.

-9-

The term "therapeutically effective amount" refers to that dosage of R-(-)-casodex which is sufficient to suppress the growth of prostate cancer, reduce androgen levels, or block a majority of peripheral androgen receptors, but insufficient to cause the adverse effects associated with racemic casodex.

The chemical synthesis of the racemic mixture of casodex can be performed by the method described in U.S. Patent 4,636,505 cited above. The (-) isomer of casodex may be obtained by resolution of the enantiomers of casodex or of precursors thereto using fractional crystallization or chromatography of diastereomeric esters of chiral acids. Other standard methods of resolution known to those skilled in the art including, but not limited to, simple crystallization and chromatographic resolution, can also be used. (See for example, E.L. Eliel, Stereochemistry of Carbon Compounds, McGraw Hill (1962) and [Wilens and Lochmuller, "Tables of Resolving Agents", Journal of Chromatography 113, 283-302 (1975)]. In addition, the carboxylic acid precursor, 3-(4-fluorophenyl)-2-hydroxy-2-methylpropanoic acid, may be resolved by fractional crystallization of diastereomeric salts with chiral amines.

The magnitude of a prophylactic or therapeutic dose of R-(-)-casodex in the acute or chronic management of disease will vary with the severity and nature of the condition to be treated and the route of administration. The dose and perhaps the dose frequency will also vary according to the age, body

-10-

weight and response of the individual patient. In general, the total daily dose range for R-(-)-casodex for the conditions described herein is from about 10 mg to about 50mg. Preferably a daily dose range  
5 should be about 20 mg to about 40 mg, while the most preferable daily dose should be about 30 mg. In managing the patient, the therapy should be initiated at a lower dose, perhaps at about 10 mg to about 20 mg, and increased up to about 40 mg or higher  
10 depending on the patient's global response. It is further recommended that patients over 65 years and those with impaired renal or hepatic function initially receive low doses and that they be titrated based on individual response(s) and blood level(s).  
15 It may be necessary to use dosages outside these ranges in some cases, as will be apparent to those skilled in the art. Further, it is noted that the clinician or treating physician will know how and when to interrupt, adjust, or terminate therapy in  
20 conjunction with individual patient response. The terms "an amount sufficient to suppress cancer but insufficient to cause said adverse effects" and "an amount sufficient to block a majority of peripheral androgen receptors but insufficient to cause said  
25 adverse effects" are encompassed by the above-described dosage amounts and dose frequency schedule.

Any suitable route of administration may be employed for providing the patient with an effective dosage of R-(-)-casodex. For example, oral, rectal,  
30 parenteral (subcutaneous, intramuscular, intravenous), transdermal, and like forms of administration may be employed. Dosage forms include tablets, troches, dispersions, suspensions,

-11-

solutions, capsules, patches, and the like.

The pharmaceutical compositions of the present invention comprise R-(-)-casodex as the active ingredient, and may also contain a pharmaceutically acceptable carrier, and optionally, other therapeutic ingredients.

The compositions of the present invention include suspensions, solutions, elixirs, or solid dosage forms. Carriers such as starches, sugars, and microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like are suitable in the case of oral solid preparations (such as powders, capsules, and tablets), and oral solid preparations are preferred over the oral liquid preparations.

Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid pharmaceutical carriers are employed. If desired, tablets may be coated by standard aqueous or nonaqueous techniques.

In addition to the common dosage forms set out above, the compounds of the present invention may also be administered by controlled release means and delivery devices such as those described in U.S. Patent Nos.: 3,845,770; 3,916,899; 3,536,809; 3,598,123; and 4,008,719, the disclosures of which are hereby incorporated by reference.

Pharmaceutical compositions of the present invention suitable for oral administration may be

-12-

presented as discrete units such as capsules, cachets, or tablets, each containing a predetermined amount of the active ingredient, as a powder or granules, or as a solution or a suspension in an aqueous liquid, a non-aqueous liquid, an oil-in-water emulsion, or a water-in-oil liquid emulsion. Such compositions may be prepared by any of the methods of pharmacy, but all methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation.

For example, a tablet may be prepared by compression or molding, optionally, with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active agent or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. Desirably, each tablet contains from about 10 mg to about 50 mg of the active ingredient, and each cachet or capsule contains from about 10 mg to about 50 mg of the active ingredient. Most preferably, the tablet, cachet or capsule contains either one of two dosages, about 20 mg or about 30 mg of R-(-)-casodex for oral administration.

-13-

The invention is further defined by reference to the following examples describing in detail the preparation of the compositions of the present invention, as well as their utility. It will be  
5 apparent to those skilled in the art that many modifications, both to materials and methods, may be practiced without departing from the purpose and interest of this invention.

The relative activity, potency and specificity  
10 of optically pure casodex and racemic casodex as an antiandrogen can be determined by pharmacological studies *in vitro* and *in vivo* according to the methods of Christiansen et al. J. Med. Chem. 33, 2094-2100 (1990). The distribution of central and peripheral  
15 activity observed in humans is not mirrored in studies in rats or monkeys, and is best demonstrated in clinical studies in humans. In such studies human volunteers are given clinically relevant doses (50 mg daily) of R-casodex and R,S-casodex for at least a  
20 month and the serum levels of testosterone are measured by standard methods well-known in the art. In the case of R-casodex, a statistically insignificant change in serum testosterone reflects the absence of central antiandrogen activity, whereas  
25 racemic casodex will exhibit statistically significant alteration in serum testosterone.

-14-

## EXAMPLES

Example 1ORAL FORMULATION

Capsules:

5	Formula	Quantity per capsule in mg		
		A	B	C
	R-(-)-casodex	10	30	50
10	Lactose	204	184	164
	Cornstarch	35	35	35
	Magnesium Stearate	1.0	1.0	1.0
	Fill Weight	250	250	250

15      The R-(-)-casodex, lactose and cornstarch are blended until uniform and then the magnesium stearate is blended into the resulting powder, which is sieved and filled into suitably sized, two-piece, hard  
20      gelatin capsules using conventional machinery. Other doses may be prepared by altering the fill weight and, if necessary, changing the capsule size to suit.



-15-

Example 2  
ORAL FORMULATION

Tablets:

	Formula	Quantity per tablet in mg		
		A	B	C
5	R-(-)-casodex	10	30	50
	Lactose	149	129	109
	Cornstarch	30	30	30
10	Water (per thousand Tablets)*	150 mL	150 mL	150 mL
	Cornstarch	60	60	60
	Magnesium Stearate	1.0	1.0	1.0
15	Compression Weight	250	250	250

---

\*The water evaporates during manufacture

20 The R-(-)-casodex is blended with the lactose until a uniform blend is formed. The smaller quantity of cornstarch is blended with the water to form the resulting corn starch paste. This is then mixed with the uniform blend until a uniform wet mass is formed. The remaining cornstarch is added to the

25 resulting wet mass and mixed until uniform granules are obtained. The granules are then screened through a suitable milling machine, using a 1/4 inch stainless steel screen. The milled granules are

30 dried in a suitable drying oven until the desired moisture content is obtained. The dried granules are then milled through a suitable milling machine,

-16-

magnesium stearate is blended in, and the resulting mixture is compressed into tablets of the desired shape, thickness, hardness and disintegration. Tablets of other strengths may be prepared by  
5 altering the ratio of active ingredient to the excipients or to the final weight of the tablet.

-17-

What is claimed is:

1. A method of treating prostate cancer in a human which comprises administering to said human a therapeutically effective amount of R-(-)-casodex, substantially free of its (+) stereoisomer.
2. The method of claim 1 wherein R-(-)-casodex is administered by parenteral, transdermal, or oral administration.
3. The method of claim 2 wherein the amount of R-(-)-casodex administered is from about 10 mg to about 50 mg per day.
4. The method of claim 3 wherein the amount administered is from about 20 mg to about 40 mg per day.
5. The method of claim 4 wherein the amount administered is about 30 mg per day.
6. The method of claim 1 wherein the amount of R-(-)-casodex is greater than approximately 90% by weight of the total weight of casodex.
7. The method of claim 1 wherein the amount of said R-(-)-casodex substantially free of its (+) stereoisomer, is administered together with a pharmaceutically acceptable carrier.
8. A pharmaceutical composition which comprises a therapeutically effective amount of R-(-)-casodex substantially free of its (+)

-18-

5 stereoisomer, and a pharmaceutically acceptable carrier.

9. The composition according to claim 8 adapted for oral administration.

10. The composition according to claim 8 adapted for parenteral delivery.

5 11. A method of treating a condition supported by androgen or caused by elevated androgen levels in a human which comprises administering to said human a therapeutically effective amount of R-(-)-casodex, substantially free of its (+) stereoisomer.

12. The method according to claim 11 wherein said condition is chosen from the group consisting of benign prostatic hypertrophy or hyperplasia, acne and hirsutism.

13. The method of claim 11 wherein R-(-)-casodex is administered by parenteral, transdermal, or oral administration.

14. The method of claim 13 wherein the amount of R-(-)-casodex administered is from about 10 mg to about 50 mg per day.

15. The method of claim 14 wherein the amount administered is from about 20 mg to about 40 mg per day.

16. The method of claim 15 wherein the amount administered is about 30 mg per day.

-19-

17. The method of claim 11 wherein the amount of R-(-)-casodex is greater than approximately 90% by weight of the total weight of casodex.

18. The method of claim 11 wherein the amount of said R-(-)-casodex substantially free of its (+) stereoisomer, is administered together with a pharmaceutically acceptable carrier.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US95/00871

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 31/275

US CL :514/522

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/522

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS Online

Search terms: casodex, androgen, antiandrogen, cancer, carcinoma, tumor

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US, A, 4,636,505 (TUCKER) 13 JANUARY 1987, column 1, line 27-column 2, line 25, column 7, lines 19-40, and column 8, lines 1-5, entire document.	1-18
X	WO, A, 91/00733 (LABRIE) 24 JANUARY 1991, page 1, page 18, and abstract, entire document.	1-18
X	JOURNAL OF MEDICINAL CHEMISTRY, Volume 31, issued 1988, Tucker et al., "Resolution of the nonsteroidal antiandrogen 4'-cyano-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-3'-(trifluoromethyl)-propionanilide and the determination of the absolute configuration of the active enantiomer", pages 885-887, entire document.	1-18

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

Special categories of cited documents:	
*A* document defining the general state of the art which is not considered to be of particular relevance	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*E* earlier document published on or after the international filing date	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*L* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	*A* document member of the same patent family

Date of the actual completion of the international search

15 MARCH 1995

Date of mailing of the international search report

11 APR 1995

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

HARRY C. CEBULAK

Telephone No. (703) 308-1235

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US95/00871

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X -- Y	PROGRESS IN CLINICAL AND BIOLOGICAL RESEARCH (MANAGEMENT OF ADVANCED CANCER OF PROSTATE AND BLADDER), Volume 260, issued 1988, Furr, "ICI 176,334: A novel non-steroidal, peripherally-selective antiandrogen", pages 13-26, entire document.	1-8, 10-13, 17-18 ----- 9, 14-16
X -- Y	HORMONE RESEARCH, Volume 32, No. 1, issued September 1989, Furr, " "Casodex"* (ICI 176,334)-A new, pure, peripherally-selective anti-androgen:preclinical studies", pages 69-76, entire document.	1-8, 10-13, 17-18 ----- 9, 14-16
X -- Y	BIOCHEMISTRY, Volume 31, issued 1992, Veldscholte et al., "Anti-androgen and the mutated androgen receptor of LNCaP cells: Differential effects on binding affinity, heat-shock protein interaction, and transcription activation", pages 2393-2399.	1-8, 10-13, 17-18 ----- 9, 14-16